GEOVAX LABS INC (GOVX) Stock Price, Forecast & Analysis
USA - NASDAQ:GOVX - US3736786068 - Common Stock
GOVX Key Statistics, Chart & Performance
The current stock price of GOVX is 0.4671 USD. In the past month the price decreased by -16.56%. In the past year, price decreased by -79.51%.
GOVX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.81 | 414.24B | ||
| AMGN | AMGEN INC | 15.34 | 180.57B | ||
| GILD | GILEAD SCIENCES INC | 15.32 | 155.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 111.21B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.48 | 73.85B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 888.92 | 59.43B | ||
| INSM | INSMED INC | N/A | 40.83B | ||
| NTRA | NATERA INC | N/A | 27.68B | ||
| BIIB | BIOGEN INC | 9.85 | 24.16B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 21.04B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.58 | 14.34B |
Related stock screener links
About GOVX
Company Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
Company Info
GEOVAX LABS INC
1900 Lake Park Drive, Suite 380
Smyrna GEORGIA 30080 US
CEO: David A. Dodd
Employees: 17
Phone: 16783847220
GEOVAX LABS INC / GOVX FAQ
Can you describe the business of GEOVAX LABS INC?
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
Can you provide the latest stock price for GEOVAX LABS INC?
The current stock price of GOVX is 0.4671 USD. The price decreased by -6.19% in the last trading session.
Does GEOVAX LABS INC pay dividends?
GOVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of GOVX stock?
GOVX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for GEOVAX LABS INC?
GEOVAX LABS INC (GOVX) operates in the Health Care sector and the Biotechnology industry.
Would investing in GEOVAX LABS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GOVX.
Can you provide the market cap for GEOVAX LABS INC?
GEOVAX LABS INC (GOVX) has a market capitalization of 13.88M USD. This makes GOVX a Nano Cap stock.
GOVX Technical Analysis
GOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GOVX. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability.
GOVX Financial Highlights
Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS increased by 91.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -463.62% | ||
| ROE | -879.26% | ||
| Debt/Equity | 0 |
GOVX Forecast & Estimates
11 analysts have analysed GOVX and the average price target is 10.1 USD. This implies a price increase of 2061.85% is expected in the next year compared to the current price of 0.4671.
For the next year, analysts expect an EPS growth of 76.85% and a revenue growth -56.94% for GOVX